Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market Perform to Outperform with a $34 price target. The rating upgrade comes despite Agios’ conflicting topline data for its Phase 3 RISE UP trial assessing mitapivat in sickle cell disease (SCD).

The trial reached its primary goal, with 40.6% of patients receiving mitapivat demonstrating a 1.0 g/dL or higher increase in hemoglobin levels, in comparison to 2.9% in the placebo group. The medication, however, did not significantly lower the annualized rate of sickle cell pain episodes.

That said, Leerink Partners sees the approaching thalassemia PDUFA date of December 7 as a near-term catalyst that is not reflected in current stock prices. The firm pointed out that this route might entail a commercialization partnership in important markets and possible approval for a wider audience compared to rival luspatercept.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a commercial-stage biopharmaceutical company focused on therapies for rare diseases, particularly in cellular metabolism. Its flagship product, PYRUKYND (mitapivat), targets hemolytic anemias, including sickle cell disease and thalassemia.

While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.